Notably, all NCL forms are progressive and currently lack disease-modifying treatments (5), except CLN2 disease, where cerliponase alfa – a recombinant form of tripeptidyl peptidase 1 (TPP1) that replaces the deficient enzyme – has demonstrated significant efficacy in slowing disease progression (6). The gene discussed is TPP1; the disease is neuronal ceroid lipofuscinosis.